Hopefully the q4 sales update and future sales guidance are stronger than this:
Needham has upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to buy, citing potential upside to Daybue sales and upcoming data for its schizophrenia drug candidate.The investment bank said a recent survey showed significant physician support for Daybue, given a lack of alternatives andsignificant unmet medical need. Needham said that its revised sale estimates for the product are now $435M for 2024, or 20% above consensus, with sales expected to exceed $600M in 2026, which is 18% above consensus.
Acadia, page-96
-
- There are more pages in this discussion • 533 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.90 |
Change
-0.200(1.00%) |
Mkt cap ! $2.530B | |||
| Open | High | Low | Value | Volume |
| $20.17 | $20.17 | $19.57 | $5.655M | 285.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1126 | $19.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.91 | 589 | 2 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |